2018
Optimal treatment for women with a persisting pregnancy of unknown location, a randomized controlled trial: The ACT-or-NOT trial
Barnhart KT, Sammel MD, Stephenson M, Robins J, Hansen KR, Youssef WA, Santoro N, Eisenberg E, Zhang H, Network F. Optimal treatment for women with a persisting pregnancy of unknown location, a randomized controlled trial: The ACT-or-NOT trial. Contemporary Clinical Trials 2018, 73: 145-151. PMID: 30243810, PMCID: PMC6231403, DOI: 10.1016/j.cct.2018.09.009.Peer-Reviewed Original ResearchConceptsOutcome measuresHuman chorionic gonadotropin concentrationRuptured ectopic pregnancyPositive pregnancy testSecondary outcome measuresExtra-uterine pregnancyInitial management strategyPrimary outcome measureChorionic gonadotropin concentrationsPatient satisfaction outcomesInitial management planAcademic medical centerEvidence-based managementAdditional ultrasonographyPersistent PULEctopic pregnancyExpectant managementAdverse eventsClinical resolutionEmpiric useGonadotropin concentrationsTransvaginal ultrasonographyTreatment complicationsTreatment armsUterine evacuationComparison of sonohysterography to hysterosalpingogram for tubal patency assessment in a multicenter fertility treatment trial among women with polycystic ovary syndrome
Christianson MS, Legro RS, Jin S, Eisenberg E, Diamond MP, Hansen KR, Vitek W, Styer AK, Casson P, Coutifaris C, Christman GM, Alvero R, Puscheck EE, Christy AY, Sun F, Zhang H, Polotsky AJ, Santoro N. Comparison of sonohysterography to hysterosalpingogram for tubal patency assessment in a multicenter fertility treatment trial among women with polycystic ovary syndrome. Journal Of Assisted Reproduction And Genetics 2018, 35: 2173-2180. PMID: 30194618, PMCID: PMC6289919, DOI: 10.1007/s10815-018-1306-2.Peer-Reviewed Original ResearchConceptsPolycystic ovary syndromeSaline infusion sonohysterographyTubal patencyClinical pregnancyOvary syndromePolycystic Ovary Syndrome IITubal patency assessmentClinical pregnancy rateDuration of infertilityAcceptable imaging modalityIntrauterine pregnancyClomiphene citrateEctopic pregnancyInfertile womenResultsAmong womenMultivariable analysisPatency assessmentTreatment armsTreatment trialsPregnancy rateMethodsSecondary analysisHysterosalpingogramLarge cohortTubes patentPatency
2015
Chlamydia trachomatis immunoglobulin G3 seropositivity is a predictor of reproductive outcomes in infertile women with patent fallopian tubes
Steiner AZ, Diamond MP, Legro RS, Schlaff WD, Barnhart KT, Casson PR, Christman GM, Alvero R, Hansen KR, Geisler WM, Thomas T, Santoro N, Zhang H, Eisenberg E, Network R. Chlamydia trachomatis immunoglobulin G3 seropositivity is a predictor of reproductive outcomes in infertile women with patent fallopian tubes. Fertility And Sterility 2015, 104: 1522-1526. PMID: 26413816, PMCID: PMC4663111, DOI: 10.1016/j.fertnstert.2015.08.022.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAntibodies, BacterialBiomarkersChi-Square DistributionChlamydia InfectionsChlamydia trachomatisEnzyme-Linked Immunosorbent AssayFallopian TubesFemaleHumansImmunoglobulin GInfertility, FemaleLinear ModelsLive BirthMultivariate AnalysisOdds RatioPredictive Value of TestsPregnancyPregnancy RatePregnancy, EctopicReproductive Techniques, AssistedRisk AssessmentRisk FactorsSerologic TestsTreatment OutcomeUltrasonographyYoung AdultConceptsEctopic pregnancySeropositive womenInfertile womenTubal patencyLive birthsPolycystic Ovary Syndrome IIChlamydia trachomatis seropositivityMultiple Intrauterine GestationsPatent fallopian tubesEnzyme-linked immunosorbentCurrent alcohol useC. trachomatis elementary bodiesOvarian stimulationCohort studyIntrauterine gestationPregnancy outcomesPrimary outcomeTreatment medicationsPatent tubesSmoking statusOutpatient clinicIgG3 antibodiesFallopian tubeRelative riskMAIN OUTCOME